Navigation Links
Halozyme Therapeutics Announces Public Offering of Common Stock
Date:9/8/2010

SAN DIEGO, Sept. 8 /PRNewswire-FirstCall/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO) today announced that it is offering to sell 8.3 million shares of its common stock pursuant to an effective shelf registration statement in an underwritten public offering. Barclays Capital Inc. is the sole book-running manager of the offering and Halozyme has granted the underwriter a thirty (30) day option to purchase up to 1,245,000 additional shares. Halozyme intends to use the net proceeds from the offering for general corporate purposes and to support further research and development of its product candidates.  

(Logo:  http://photos.prnewswire.com/prnh/20100302/LA63139LOGO)

(Logo:  http://www.newscom.com/cgi-bin/prnh/20100302/LA63139LOGO)

This press release does not constitute an offer to sell, or the solicitation of an offer to buy, these securities, nor will there be any sale of these securities in any state in which such offer, solicitation or sale is not permitted. Electronic copies of the preliminary prospectus supplement and accompanying prospectus may be obtained from: Barclays Capital Inc., c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717; Barclaysprospectus@broadridge.com (phone: 888-603-5847).

Halozyme has filed a registration statement (including a base prospectus) with the Securities and Exchange Commission, or SEC, for an offering to which this communication relates. Before you invest, you should read the prospectus in that registration statement and the related prospectus supplements and the other documents that Halozyme has filed or will file with the SEC for more complete information about Halozyme and this offering. You may access these documents when available for
'/>"/>

SOURCE Halozyme Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Halozyme Therapeutics Completes Enrollment in Chemophase Phase I/IIa Clinical Trial for Superficial Bladder Cancer
2. Halozyme Therapeutics Announces Peer-Reviewed Publications of the INFUSE-LR Clinical Trial Results and Clinical Practice Experience With Hylenex
3. Halozyme Therapeutics Presents Pre-Clinical Studies of Systemic Delivery of Pegylated rHuPH20 Enyzme in Prostate Cancer Models at American Association for Cancer Research Conference
4. Halozyme Therapeutics Presents Findings on Combinations of rHuPH20 Enzyme With Bisphosphonates at the American Association for Cancer Research Conference
5. Halozyme Therapeutics Announces Phase I Clinical Trial Results Demonstrating that the Combination of Recombinant Human Hyaluronidase (rHuPH20) With Humulin R(R) and with Humalog(R) Yields Faster, More Physiologic Insulin Kinetics and Better Predictability
6. Halozyme Therapeutics Announces That Chemophase Meets Primary Endpoint in Phase I/IIa Clinical Trial
7. Halozyme Therapeutics Announces Positive Findings With Pegylated Enzyme in Prostate Cancer Models
8. Halozyme Therapeutics Announces Roche Begins Phase 1 Clinical Trial and Selects Fourth Exclusive Biologic Target
9. Halozyme Therapeutics Begins Phase 1 Clinical Trial of Bisphosphonate Administered With rHuPH20 Enzyme
10. Halozyme Provides HYLENEX® Product Reintroduction Update
11. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/27/2015)... Columbia and MENLO PARK, ... DelMar Pharmaceuticals, Inc. (OTCQX: DMPI) ("DelMar" and ... and commercializing proven cancer therapies in new orphan ... subscriptions from institutional and accredited investors for a ... of common stock and 3.35 million common stock ...
(Date:7/27/2015)... 27, 2015 Bloomage BioTechnology Corporation Limited ("Bloomage" ... cooperation with the South Korean BioTech Company Medytox Inc. ... Medybloom to develop and promote Type A Botulinum Toxin ... Medytox, the Botulinum Toxin brand, occupies ... the fourth company in the world successfully developed and ...
(Date:7/27/2015)...   DocResponse was ranked the most ... peer-reviewed study , "Evaluation of symptom checkers ... in the July issue of The British Medical ... School researchers determined that performance of online symptom ... diagnosis first in standardized patient evaluations more often ...
Breaking Medicine Technology:DelMar Pharmaceuticals Announces Financing Update and Initial Subscriptions of $2.0 million in Registered Direct Offering 2DelMar Pharmaceuticals Announces Financing Update and Initial Subscriptions of $2.0 million in Registered Direct Offering 3Bloomage (00963.HK) and Medytox Inc. set up a Joint Venture To Jointly Develop Botulinum Toxin Market in China 2Bloomage (00963.HK) and Medytox Inc. set up a Joint Venture To Jointly Develop Botulinum Toxin Market in China 3Harvard Study Finds DocResponse Most Accurate Medical Symptom Checker/Diagnostics Application 2Harvard Study Finds DocResponse Most Accurate Medical Symptom Checker/Diagnostics Application 3
... BEVERLY, Mass., March 8, 2011 Cellceutix Corporation (Pink ... has entered into a Confidential Disclosure Agreement (CDA) pertaining ... world,s largest pharmaceutical companies. Cellceutix CEO, ... to be signing a CDA on a compound before ...
... Inc. (Nasdaq: CPIX ), a specialty pharmaceutical ... announced fourth quarter and full year 2010 financial results. ... December 31, 2010, net revenue was $12.8 million, up 20% ... quarterly revenue growth was largely driven by 16% year-over-year growth ...
Cached Medicine Technology:Cellceutix Reports Confidential Disclosure Agreement Signed With Major Pharmaceutical Company 2Cellceutix Reports Confidential Disclosure Agreement Signed With Major Pharmaceutical Company 3Cumberland Pharmaceuticals Reports Fourth Quarter and Full Year 2010 Financial Results 2Cumberland Pharmaceuticals Reports Fourth Quarter and Full Year 2010 Financial Results 3Cumberland Pharmaceuticals Reports Fourth Quarter and Full Year 2010 Financial Results 4Cumberland Pharmaceuticals Reports Fourth Quarter and Full Year 2010 Financial Results 5Cumberland Pharmaceuticals Reports Fourth Quarter and Full Year 2010 Financial Results 6Cumberland Pharmaceuticals Reports Fourth Quarter and Full Year 2010 Financial Results 7Cumberland Pharmaceuticals Reports Fourth Quarter and Full Year 2010 Financial Results 8Cumberland Pharmaceuticals Reports Fourth Quarter and Full Year 2010 Financial Results 9Cumberland Pharmaceuticals Reports Fourth Quarter and Full Year 2010 Financial Results 10Cumberland Pharmaceuticals Reports Fourth Quarter and Full Year 2010 Financial Results 11Cumberland Pharmaceuticals Reports Fourth Quarter and Full Year 2010 Financial Results 12Cumberland Pharmaceuticals Reports Fourth Quarter and Full Year 2010 Financial Results 13
(Date:7/28/2015)... ... July 28, 2015 , ... A new study published by HealthDay News ... " sheds light on a possible new treatment option for people living with fibromyalgia ... HBOT sessions, at least five per week, patients experienced a significant decrease in pain, ...
(Date:7/28/2015)... (PRWEB) , ... July 28, 2015 , ... There has ... most people think of highways, bridges and railroads, often overlooked is the over ... our homes and buildings and into sewage treatment facilities. According to the American ...
(Date:7/28/2015)... ... July 28, 2015 , ... Please join us for the 5th Annual Step for Hope ... at Gary Avenue and Lies Road in Carol Stream. All are welcome. , Now ... provide education and help to support individuals and families affected by a brain aneurysm. ...
(Date:7/28/2015)... ... July 28, 2015 , ... American Sentinel University has been ... for Geisinger Health System (GHS), one of the nation’s largest integrated health ... nurses with access to American Sentinel’s affordable, flexible and CCNE-accredited RN to BSN ...
(Date:7/28/2015)... , ... July 28, 2015 , ... Scientel ... NoSQL Now! Conference, August 18-20 at the McHenry Convention Center in San Jose, ... in booth #104. , Scientel’s presentation on Multi-Modeling and the industry’s first polymorphic database ...
Breaking Medicine News(10 mins):Health News:Recovery Specialists Discuss How Oxygen Therapy Can Ease Fibromyalgia 2Health News:Recovery Specialists Discuss How Oxygen Therapy Can Ease Fibromyalgia 3Health News:With an Infrastructure Spending Bill on the Horizon, RestorationEze Discusses the Impact an Aging Sewer System is Having on Homeowners 2Health News:With an Infrastructure Spending Bill on the Horizon, RestorationEze Discusses the Impact an Aging Sewer System is Having on Homeowners 3Health News:5th Annual Step for Hope 5K Run/Walk Event in Carol Stream, IL to Benefit Renowned Brain Aneurysm Foundation 2Health News:American Sentinel University Selected to Provide Online RN to BSN Cohorts to Geisinger Health System 2Health News:American Sentinel University Selected to Provide Online RN to BSN Cohorts to Geisinger Health System 3Health News:American Sentinel University Selected to Provide Online RN to BSN Cohorts to Geisinger Health System 4Health News:Scientel Selected to Present at 2015 NoSQLNow! Conference, San Jose August 18-20 2Health News:Scientel Selected to Present at 2015 NoSQLNow! Conference, San Jose August 18-20 3
... Lower potassium levels in the blood may help explain why ... 2 diabetes as whites, according to a new study by ... part of diabetes prevention may someday prove as easy as ... mean people should run out and start taking potassium supplements," ...
... 2 (HealthDay News) -- Babies born to women who smoke ... have a congenital heart defect than are the offspring of ... increased risk ranged from 20 percent to 70 percent, varying ... that obstruct the flow of blood from the right side ...
... Reporter , TUESDAY, March 1 (HealthDay News) -- On ... Administration approves medical devices with too little oversight comes ... without being adequately tested on women, despite an agency ... heart valves, pacemakers, defibrillators and stents get implanted in ...
... The National Eye Institute (NEI) and Food and Drug ... functional vision-related endpoints for clinical trials of visual prostheses ... visual acuity, visual fields and contrast sensitivity. These assessments ... test outcomes. Today, functional vision outcomes ...
... By Amanda Gardner HealthDay Reporter , TUESDAY, March 1 ... some people of white European descent who have type 2 diabetes. ... may prove a future target for treatments, among other benefits, say ... Journal of the American Medical Association . As with ...
... , TUESDAY, March 1 (HealthDay News) -- A new international ... States and elsewhere may be infected with human papillomavirus (HPV), ... tumors. The finding could help public health experts ... study authors say. "The incidence of genital HPV infection ...
Cached Medicine News:Health News:Potassium levels possible key to racial disparity in Type 2 diabetes 2Health News:Smoking During Early Pregnancy May Put Baby's Heart at Risk 2Health News:Heart Devices Not Tested Enough in Women: Study 2Health News:Heart Devices Not Tested Enough in Women: Study 3Health News:Visual prostheses: Symposium to explore combining functional endpoints 2Health News:Scientists Spot Another Gene Behind Type 2 Diabetes 2Health News:Half of U.S. Men Infected With HPV, Study Reveals 2
"Ganzfeld" stimulations for flash VEP, flash ERG and sensory EOG. Complies with international standards of electrophysiology....
... Slit Lamp is the ideal instrument combination: in ... handy slit lamp to an indirect ophthalmoscope. ... anterior and posterior ocular segments, the HSO 10 ... in miniature. Outstanding benefits for your work include ...
... Analyzers Model 350 and Model 360 ... lensometry for your practice. ,Simple to ... gives fast and accurate lens neutralization ... lenses, contact lenses, polycarbonate and other ...
... contains a plunger style advance, or a ... for multiple use. The injector is made ... STAAR cartridges. These injectors are sold sterile, ... This system was designed specifically for easy ...
Medicine Products: